Company: CERO
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001213900-25-032134
Chunk: 2100

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 2
Chunk 2100
---
 Cash flows from financing activities: 

    Proceeds from issuance of convertible notes 
     -  
     -  
     605,230 
  
    Issuance costs for convertible notes 
     -  
     -  
     (41,193)
  
    Common stock subscription deposit 
     -  
     -  
     1,875 
  
    Cash proceeds from exercise of common stock options 
     -  
     -  
     5,766 
  
    Proceeds from issuance of Series A Preferred Stock, net of issuance costs 
     6,757,700  
     -  
     - 
  
    Advances from shareholder 
     13,731  
     -  
     - 
  
    Payment of sponsor loans 
     (19,715) 
     -  

    Payments for short term borrowings 
     (402,514) 
     -  

    Proceeds from short-term borrowings, net 
     408,052  
     -  
     - 
  
    Proceeds from share purchases under ELOC, net of issuance costs 
     4,809,703  
     -  
     - 
  
    Proceeds received from sale of Series B Preferred Stock, net of issuance costs 
     418,316  
     -  
     - 
  
    Proceeds received from sale of Series C Preferred Stock, net of issuance costs 
     803,561  
     -  
     - 
  
    Proceeds from Series A preferred warrant exercises 
     938,800  
     -  
     - 
  
    Net cash provided by financing activities 
     13,727,634  
     -  
     571,678 

    Net increase (decrease) in cash and cash equivalents 
     1,449,065  
     (637,400) 
     (5,218,309)

    Cash, restricted cash and cash equivalents at beginning of period 
     1,877,995  
     1,601,255  
     6,819,564 

    Cash, restricted cash and cash equivalents at end of period 
    $3,327,060  
    $963,855  
    $1,601,255